Special 11/2012

  • BIO-Europe 2012

    Meetings, Trends and Partnerships:

    Four years after the collapse of Lehman Brothers, global capital markets still haven’t recovered – especially in biotechnology. Along with VCs, Big Pharma is a significant contributor to that financing pool, which is why biotech companies depend on major players’ appetite for innovation to survive in turbulent times. The BIO-Europe conference helps firms making those and other connections. With more than 3,500 attendees from 1,600 companies, the event is the number one partnering platform in Europe.

Volume 2015

Volume 2014

Volume 2013

Volume 2012

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/magazine/spezial/2012/11.html

Current issue

All issues

Events

All Events

Product of the week

Products